Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Natasha on +44 1494 818 053 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Natasha Wilson
Executive Recruiter
+44 1494 818 053

I could not speak more highly of Zenopa and my Account Manager. From the word go I found them to be fully professional and helpful keeping me updated all the way through the recruitment process and al...
Phil, 2013

Pfizer beats forecasts with second-quarter profits

3 August 2011 00:00 in Pharmaceutical Company Financials

Pfizer has reported second-quarter profits that exceeded analysts' estimates, despite revenue declining as a result of expiring patents.

The world's biggest pharmaceutical firm said profit excluding some items was 60 cents a share - one cent higher than the average estimate of 16 experts polled by Bloomberg.

Second-quarter revenues stood at $17 billion (10.3 billion pounds), a decrease of one percent compared with the corresponding period last year.

Ian Read, president and chief executive of Pfizer, said the performance was "in line with our expectations".

He added: "We will continue to invest in areas that will enhance our presence, expand the breadth of our portfolio and position our businesses to better capitalise on high-growth opportunities."

Pfizer is preparing to face generic competition to Lipitor - the world's best-selling drug - from November, when it will lose the exclusive rights to the cholesterol control treatment.

According to the firm's statement, sales of Lipitor stood at $2.59 billion in the second quarter of 2011.ADNFCR-8000103-ID-800682960-ADNFCR

Other news stories from 03/08/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd